

Chinese Journal of Pharmacovigilance ›› 2026, Vol. 23 ›› Issue (5): 506-512.
DOI: 10.19803/j.1672-8629.20260288
Previous Articles Next Articles
JIN Longlong1, WEN Hairuo2,3, CHEN Zhonglan1, YANG Huiying1, WANG Qing1, SHAO Changjun1, WU Xianfu1,*
Received:2026-04-09
Published:2026-05-20
CLC Number:
JIN Longlong, WEN Hairuo, CHEN Zhonglan, YANG Huiying, WANG Qing, SHAO Changjun, WU Xianfu. Research Progress in Detection Methods of Nitrosamine Drug Substance-Related Impurities[J]. Chinese Journal of Pharmacovigilance, 2026, 23(5): 506-512.
| [1] HUANG P,CATALANO A.Changes in Secondary Structure of DNA of Rat Embryos Following Treatment with 1,2-Diethylhydrazine and Dimethylnitrosamine in vivo[J]. Teratog Carcinog Mutagen, 1994, 14(2):53-64. [2] IWAKUMA T, SAKUMI K, NAKATSURU Y, et al.High Incidence of Nitrosamine-Induced Tumorigenesis in Mice Lacking DNA Repair Methyltransferase[J]. Carcinogenesis, 1997, 18(8):1631-1635. [3] SNODIN DJ, TREJO-MARTIN A, PONTING DJ, et al.Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic Potency[J]. Chemical Research in Toxicology, 2024, 37(2):181-198. [4] NUDELMAN R, KOCKS G, MOUTON B, et al.The Nitrosamine “Saga”:Lessons Learned from Five Years of Scrutiny[J]. Organic Process Research & Development, 2023, 27(10):1719-1735. [5] FDA. Recommended Analytical Testing Methods[EB/OL]. (2024-02-23)[2026-04-08]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cder-nitrosamine-impurity-acceptable-intake-limits#testing. [6] Official Medicines Control Laboratories. Methods for Determination of Nitrosamine Drug Substance-Related Impurities (NDSRIs) and Intermediate-Related Contaminants[EB/OL].[2026-04-08]. https://www.edqm.eu/en/nitrosamine-testing-activities-of-the-omcl-network. [7] Health Sciences Authority. Nitrosamine Impurities in Medicines[EB/OL]. (2022-5-20)[2026-04-08]. https://www.hsa.gov.sg/therapeutic-products/medicines-quality-and-compliance-monitoring/nitrosamine-impurities-in-medicines/test-methods. [8] HUANG HW, YUAN S, ZHANG QS, et al.Determination of Genotoxic Impurity N-nitroso-propranolol in Propranolol Hydrochloride Sustained-Release Tablets by UHPLC-MS/MS[J]. Journal of Pharmaceutical Research(药学研究), 2023, 42(7):481-484. [9] GUO CC, WEN SS, XU YW, et al.Determination of Trace N-nitroso-propranolol in Propranolol Hydrochloride Sustained Release Tablets by UHPLC-Q-Orbitrap HRMS[J]. Herald of Medicine(医药导报), 2025, 44(4):628-633. [10] TWOHIG M, WAGH P, BARTLETT A.Quantitation of N-nitroso-propranolol in Drug Substance Using LC-MS/MS[G]. Abstracts of Papers, ACS Fall Meeting, 2024. [11] FUKUDA S, NAKASE Y, IMAGAKI K, et al.Simple and Practical Method for the Quantitative High-Sensitivity Analysis of N-nitroso Duloxetine in Duloxetine Drug Products Utilizing LC-MS/MS[J]. ACS Omega, 2024, 9(11):13440-13446. [12] BOPPANA SSSK, CHAGARLAMUDI KK, DAMARAPURAPU R, et al.High-Sensitivity LC-MS/MS Approach for Accurate Quantification of N-nitroso Duloxetine in Duloxetine Pharmaceutical Formulations[J]. Biomedical Chromatography, 2025, 39(6):e70101. [13] GANESH P, RAJU BVN, RAO BM, et al.Characterization and Quantitation of N-nitroso Duloxetine Impurity in Duloxetine Hydrochloride Drug Substance[J]. Asian Journal of Chemistry, 2023, 35(11):2789-2796. [14] JAYAVARAPU NC, SENGUPTA S, BAPATU HR, et al.Development and Validation of RP-HPLC Method for the Detection of N-nitroso Meglumine in Pharmaceutical Products[J]. Biomedical Chromatography, 2025, 39(6):e70064. [15] RAGHUVARAN G, SATLA SR.A Highly Sensitive Green Analytical UHPLC-MS/MS Method for the Quantification of Trace Level of N-nitroso Meglumine Impurity in Tafamidis Meglumine Applying the Quality by Design[J]. Asian Journal of Chemistry, 2025, 37(8):1949-1958. [16] THAKKAR K, SOLANKI R, PATEL R.Ultrasensitive Liquid Chromatography Triple Quadrupole Mass Spectrometry Detection and Quantification of N-nitroso-meglumine in Tafamidis Meglumine Capsules Using Electrospray Ionization[J]. Separation Science Plus, 2025, 8(8):e70091. [17] WANG YX, YUAN S, CHEN H, et al.Synthesis and Detection of Potential Genotoxic Impurities in Nebivolol Hydrochloride[J]. Chinese Journal of New Drugs(中国新药杂志), 2025, 34(1):73-79. [18] HAN JR, XU YM, HAO LJ, et al.Determination of Potential Genotoxic Impurities in Labetalol Hydrochloride by HPLC-MS/MS Method[J]. Journal of Hebei University of Science and Technology(河北科技大学学报), 2024, 45(3):277-282. [19] WANG L, CAO L, FAN YL, et al.Determination of Nitrosamine Impurities in Bevantolol Hydrochloride by HPLC-MS/MS[J]. Tianjin Pharmacy(天津药学), 2025, 37(5):526-545. [20] KWON S, AHN SH, CHANG YH, et al.Development and Validation of a Sensitive LC-MS/MS Method for the Determination of N-nitroso-atenolol in Atenolol-Based Pharmaceuticals[J]. Separations, 2025, 12(5):122. [21] YUAN S, CHEN H, ZHANG QS, et al.Determination of Potential Genotoxic Impurity in Enalaoril Hydrochlorothiazide Preparation by UHPLC-MS/MS Method[J]. Journal of Pharmaceutical Research(药学研究), 2023, 42(8):579-583. [22] YUAN S, CHEN H, ZHANG QS, et al.Determination of Potential Genotoxic Impurity N-nitrosovarenicline in Varenicline Tartrate by UPLC-MS/MS[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2023, 40(9):1219-1223. [23] YUAN S, LIU Y, ZHANG QS, et al.Determination of Genotoxic Impurity NTTP in Sitagliptin Phosphate by UPLC-MS/MS[J]. Journal of Pharmaceutical Research(药学研究), 2023, 42(12):1000-1004. [24] CHAO RR, CHEN KR, HANG TJ, et al.Determination of N-nitroso-Trimetazidine as the Potential Genotoxic Impurity in Hydrochloride Trimetazidine by HPLC-MS/MS[J]. Pharmaceutical and Clinical Research(药学与临床研究), 2025, 33(3):227-230. [25] ZENG Y, TEO J, LIM JQ, et al.Determination of N-nitroso Folic Acid in Folic Acid and Multivitamin Supplements by LC-MS/MS[J]. Food Additives & Contaminants:Part A, 2024, 41(1):1-8. [26] MANDAPAKA MK, BODDU V.Identification and Quantification of Potential Genotoxic Impurity N-nitroso Isoproterenol in Bradycardia Drug Isoproterenol Hydrochloride by LC-MS/MS Technique[J]. Analytical Chemistry Letters, 2024, 14(6):935-950. [27] YADAV AD, ALASPURE AC, LODHA SR, et al.Ultrasensitive LC-MS/MS Quantitation of the N-nitroso-dabigatran Etexilate Impurity in Dabigatran Etexilate Mesylate Using an Electrospray Ionization Technique[J]. Analytical Methods, 2025, 17(8):1797-1803. [28] CHITRA P, PREMAKUMARI KB, ARUN B.An Efficient LC-MS/MS Method for Determining N-nitroso Tofacitinib Toxicity in the Tablet Form[J]. Current Analytical Chemistry, 2025, 21(5):521-534. [29] WEI MY, HUANG B, LIU SZ, et al.Determination of N-nitrosoprimaquine Genotoxic Impurity in Primaquine Phosphate API by UPLC-MS/MS[J]. Guangdong Chemical Industry(广东化工), 2025, 52(16):117-119. [30] GUO CC, CHENG CL, XU YW, et al.Determination of Genotoxic Impurity N-nitroso Atomoxetine in Atomoxetine Hydrochloride Capsules by Ultra High-Performance Liquid Chromatography-Q-Orbitrap High-Resolution Mass Spectrometry[J]. Chinese Journal of Pharmaceutical Analysis(药物分析杂志), 2025, 45(12):2107-2115. [31] UPPALA R, PRABHU RC, MARUTHAPILLAI A, et al.Development of an UPLC-MS/MS Approach to Detect and Quantify N-nitroso Mirabegron in Mirabegron[J]. Rapid Communications in Mass Spectrometry, 2024, 38(22):e9911. [32] RALLIS GN, PAPAKANAKI VN, GKATZIOU DG, et al.A Compre-hensive UPLC-MS/MS Method for the Determination of N-nitroso Metamizole EP Impurity C in Metamizole Drug Products[J]. Journal of Liquid Chromatography & Related Technologies, 2025, 48(6-10):159-167. [33] VELE VT, MORE K, MOHAN A, et al.LC-MS/MS Method for the Determination and Quantification of a N-nitroso-dorzolamide in the Dorzolamide Hydrochloride Active Pharmaceutical Ingredient[J]. European Journal of Biomedical and Pharmaceutical Sciences, 2024, 11(3):149-154. [34] KUMAR V, BALTHU L, PEPAKAYALA S, et al.N-nitroso-vildagliptin, a New N-nitrosamine Drug Substance Related Impurity (NDSRI) of Vildagliptin-An Antidiabetic Drug:Synthesis, Characterization and Development of Sensitive LC-MS/MS Method[J]. Chromatographia, 2025, 88(10):791-799. [35] NAKKA S, KATARI NK, MUCHAKAYALA SK, et al.Synthesis and Trace-Level Quantification of Mutagenic and Cohort-of-Concern Ciprofloxacin Nitroso Drug Substance-Related Impurities (NDSRIs) and Other Nitroso Impurities Using UPLC-ESI-MS/MS-Method Optimization Using I-Optimal Mixture Design[J]. ACS Omega, 2024, 9(8):8773-8788. [36] LI SH, DONG LX, LIN HQ, et al.Simultaneous and Trace Level Quantification of Two Potential Genotoxic Impurities in Valsartan Drug Substance Using UPLC-MS/MS[J]. Journal of Pharmaceutical and Biomedical Analysis, 2022, 212:114630. [37] MANDAPAKA MK, BODDU V.A Simple and Rapid Analytical Method to Detect and Quantify the N-nitroso Desmethyl Diltiazem Impurity by Liquid Chromatography-Tandem Mass Spectrometry in Diltiazem Hydrochloride[J]. Separation Science Plus, 2025, 8:e70065. [38] VALLAMKONDA B, YARGUNTLA SR, CHALLA RR.Development and Validation of a Highly Sensitive LC-MS/MS Method for Quantification of Mutagenic N-nitroso Desmethyl Citalopram in Drug Formulations[J]. Separation Science Plus, 2025, 8:e70011. [39] RAJANA N, BALAJI SKK.Quantitative LC-MS/MS Method for Simultaneous Quantification of N-nitroso-Berotralstat and N-nitroso-Boc-Berotralstat in Berotralstat·HCl[J]. Separation Science Plus, 2025, 8(5):e70046. [40] CHAGARLAMUDI K, DAMARAPURAPU R, MANGLIGE VK, et al.High-Sensitivity LC-MS/MS Method for Precise Quantification of N-nitroso Sertraline in the Antidepressant Sertraline Drug Products[J]. Separation Science Plus, 2025, 8(5):e70048. |
| [1] | JIN Longlong, WEN Hairuo, YANG Huiying, WANG Qing, SHAO Changjun, WU Xianfu. Research Progress in Nitrosamine Drug Substance-Related Impurity Synthesis [J]. Chinese Journal of Pharmacovigilance, 2026, 23(5): 500-505. |
| [2] | LIU Suyan, LI Chunying, YI Yan, ZHAO Yong, HAN Jiayin, PAN Chen, ZHANG Yushi, YU Yuan, LIU Qing, LIANG Aihua. Seed-Removal and Alkaline-Treatment of Aristolochia contorta Bge. in Zhisou Huatan Pills and Quality Control: a Detoxification Study [J]. Chinese Journal of Pharmacovigilance, 2026, 23(1): 88-94. |
| [3] | YANG Yifan, YANG Yanwei, ZHANG Di, XIE Yin, ZHANG Yong, CHEN Xulin, GAO Sutao, GENG Xingchao, QU Zhe. Quality Control and Test Methods of Human Induced Pluripotent Stem Cells [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 728-734. |
| [4] | BAI Xue, LI Jingcheng, LI Xueli. Research Advances in Roles of Traditional Chinese Medicine in Improving Myocardial Infarction by Regulating Mitochondrial Homeostasis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(12): 1328-1333. |
| [5] | LI Xinghong, ZHU Xiaoyu, TIAN Guanghuan, DUAN Cancan, DENG Yong, ZHANG Jianyong, WU Hongwei. Quality Evaluation of GEI HERBA Based on Electronic Eye and Fingerprint [J]. Chinese Journal of Pharmacovigilance, 2025, 22(11): 1229-1235. |
| [6] | LIU Bo, YUAN Yanan, WANG Yue, CHENG Shuqian, LU Zhiguo, FAN Huihong, SUN Huimin. Key Technologies for Quality Control of Oligonucleotide Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 1-9. |
| [7] | SUN Deyang, SUN Jiabei, LI Wenlong, JIA Juanjuan, ZHANG Wenzai, LIU Yan, HUANG Haiwei, YAO Jing. Assignment of Chemical Reference Substance of Aminopolyether -a Key Impurity in Fludeoxyglucose [18F] Injection [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 43-46. |
| [8] | PEI Yusheng, XU Lin, ZHAO Yuxin, CAI Tong, HUA Xiaodong. Low Endotoxin Recovery and Mitigation Strategies [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 72-75. |
| [9] | LU De, XU Wenyan, LIU Jinxin, PEI Yusheng. Discussion and analysis of bacterial endotoxin problems in FDA warning letters [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 857-862. |
| [10] | ZHANG Xiaoming, LYU Ping, HU Xinyue, DING Xiaoli, LI Jing, LIANG Chenggang. Detection of single-chain precursor residues in insulin glargine by ELISA [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 290-294. |
| [11] | WANG Dandan, WANG Ying, YAO Lingwen, LIU Yuanxi, JIN Hongyu, MA Shuangcheng. Determination of residual solvents in extract of Coleus amboinicus by headspace-gas chromatography [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 295-299. |
| [12] | WEN Hairuo, HUANG Qin, HAN Suqin, JIANG Hua, QIN Chao, SHI Haokun, ZHAO Tingting, GENG Xingchao, WANG Qi. Mutagenicity risk of N-nitrosobumetanil in SD rats [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 307-312. |
| [13] | WANG Changshun, WANG Xiaolei, DUAN Jiping, YUAN Hao, LIU Yongli, ZHAO Ding. Effect of sulfur fumigation on quality of Angelica dahurica and alternative processing methods in producing areas [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 355-360. |
| [14] | LEI Jingqi, ZHANG Zezhao, REN Dong, WANG Xinguo, NIU Liying. Determination of 15 Chemical Constituents in Dandelion Leaves from Different Areas of Production Based on UPLC-MS/MS [J]. Chinese Journal of Pharmacovigilance, 2024, 21(11): 1256-1263. |
| [15] | LI Yiwen, CAO Keming, LAN Yuze, SU Shuang, MA Hongliang, ZHANG Lili, CHANG Xiaohong, LI Bo. Rational Use of Traditional Chinese Medicine Decoction Pieces in Outpatient Clinic of a Hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(11): 1293-1298. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||